Jennifer Altreuter

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe et al. · The Lancet Oncology · 2022 · 225 citations · Full text

Medicine, Previous Pd, Bronchial Neoplasm +5

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi et al. · Cancer Cell · 2023 · 91 citations · Full text

Cancer Immunosurveillance, Autoimmune Disease, Immunology +10

The Ubiquitin-Specific Peptidase USP15 Regulates Human Papillomavirus Type 16 E6 Protein Stability

Robin M. Vos, Jennifer Altreuter, Elizabeth White et al. · Journal of Virology · 2009 · 78 citations · Full text

Viral Replication, Molecular Biology, Viral Structural Protein +16

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Livius Penter, Yang Liu, Jacquelyn O. Wolff et al. · Blood · 2023 · 48 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Pharmacotherapy +20

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Edwin R. Parra, Jiexin Zhang, Dzifa Y. Duose et al. · Clinical Cancer Research · 2024 · 36 citations · Full text